Home › Therapeutic areas › Infectious Disease › Hepatitis B
Hepatitis B (5 companies)
Companies with an active program in Hepatitis B.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ADMA | Adma Biologics | ImmunologyInfectious Disease Rare | 1 | Approved | $2.82B | 4 |
| ENTA | Enanta Pharmaceuticals | DermatologyImmunology+1 | 1 | Approved | $320M | 7 |
| IMCR | Immunocore | DermatologyInfectious Disease+2 | 1 | Approved | $1.60B | 15 |
| IONS | Ionis Pharmaceuticals | CardiovascularHematology+5 Rare | 1 | Approved | $6.55B | 29 |
| DTIL | Precision Biosciences | Infectious DiseaseMetabolic+1 Rare | 1 | Phase 1 | $296M | 5 |
No companies match.